 Ovarian Neoplasms
"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Descriptor ID |
D010051
|
| MeSH Number(s) |
C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
|
| Concept/Terms |
Ovarian Neoplasms- Ovarian Neoplasms
- Neoplasm, Ovarian
- Ovarian Neoplasm
- Ovary Neoplasms
- Neoplasm, Ovary
- Neoplasms, Ovary
- Ovary Neoplasm
- Neoplasms, Ovarian
Ovary Cancer- Ovary Cancer
- Cancer, Ovary
- Cancers, Ovary
- Ovary Cancers
- Ovarian Cancer
- Cancer, Ovarian
- Cancers, Ovarian
- Ovarian Cancers
- Cancer of Ovary
- Cancer of the Ovary
|
Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".
This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 0 | 2 | | 1994 | 1 | 2 | 3 | | 1995 | 3 | 0 | 3 | | 1996 | 4 | 1 | 5 | | 1997 | 2 | 0 | 2 | | 1998 | 3 | 1 | 4 | | 1999 | 1 | 1 | 2 | | 2000 | 3 | 0 | 3 | | 2002 | 1 | 0 | 1 | | 2003 | 5 | 1 | 6 | | 2004 | 2 | 0 | 2 | | 2005 | 6 | 1 | 7 | | 2006 | 2 | 0 | 2 | | 2007 | 11 | 0 | 11 | | 2008 | 6 | 3 | 9 | | 2009 | 4 | 0 | 4 | | 2010 | 10 | 5 | 15 | | 2011 | 12 | 2 | 14 | | 2012 | 8 | 0 | 8 | | 2013 | 12 | 1 | 13 | | 2014 | 6 | 1 | 7 | | 2015 | 13 | 1 | 14 | | 2016 | 22 | 1 | 23 | | 2017 | 16 | 0 | 16 | | 2018 | 14 | 3 | 17 | | 2019 | 17 | 0 | 17 | | 2020 | 20 | 1 | 21 | | 2021 | 16 | 2 | 18 | | 2022 | 16 | 0 | 16 | | 2023 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
Zhang C, Guo Q, Chen L, Wu Z, Yan XJ, Zou C, Zhang Q, Tan J, Fang T, Rao Q, Li Y, Shen S, Deng M, Wang L, Gao H, Yu J, Li H, Zhang C, Nowsheen S, Kloeber J, Zhao F, Yin P, Teng C, Lin Z, Song K, Yao S, Yao L, Wu L, Zhang Y, Cheng X, Gao Q, Yuan J, Lou Z, Zhang JS. A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors. Signal Transduct Target Ther. 2023 May 10; 8(1):183.
-
Holmberg R, Robinson M, Gilbert SF, Lujano-Olazaba O, Waters JA, Kogan E, Velasquez CLR, Stevenson D, Cruz LS, Alexander LJ, Lara J, Mu EM, Camillo JR, Bitler BG, Huxford T, House CD. TWEAK-Fn14-RelB Signaling Cascade Promotes Stem Cell-like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse. Mol Cancer Res. 2023 02 01; 21(2):170-186.
-
Thomson CA, Crane TE, Miller A, Gold MA, Powell M, Bixel K, Van Le L, DiSilvestro P, Ratner E, Lele S, Guntupalli S, Huh W, Robertson SE, Modesitt S, Casey AC, Basen-Engquist K, Skiba M, Walker J, Kachnic L, Alberts DS. Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors. Gynecol Oncol. 2023 03; 170:11-18.
-
McMellen A, Yamamoto TM, Qamar L, Sanders BE, Nguyen LL, Ortiz Chavez D, Bapat J, Berning A, Post MD, Johnson J, Behbakht K, Nurmemmedov E, Chuong EB, Bitler BG. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. Mol Cancer Res. 2023 01 03; 21(1):3-13.
-
Wrobel J, Harris C, Vandekar S. Statistical Analysis of Multiplex Immunofluorescence and Immunohistochemistry Imaging Data. Methods Mol Biol. 2023; 2629:141-168.
-
Smith LP, Brubaker LW, Wolsky RJ. It Does Exist! Diagnosis and Management of Thyroid Carcinomas Originating in Struma Ovarii. Surg Pathol Clin. 2023 Mar; 16(1):75-86.
-
Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
-
Huang TT, Burkett SS, Tandon M, Yamamoto TM, Gupta N, Bitler BG, Lee JM, Nair JR. Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer. Oncogene. 2022 11; 41(46):5020-5031.
-
Kammer MN, Rowe DJ, Deppen SA, Grogan EL, Kaizer AM, Bar?n AE, Maldonado F. The Intervention Probability Curve: Modeling the Practical Application of Threshold-Guided Decision-Making, Evaluated in Lung, Prostate, and Ovarian Cancers. Cancer Epidemiol Biomarkers Prev. 2022 09 02; 31(9):1752-1759.
-
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath Iii CA, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. NCCN Guidelines? Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022 09; 20(9):972-980.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|